Evidence map›Paper›PMID 38496947›Full record

ArticleACS omega2024

Immune Potentiation of PLGA Controlled-Release Vaccines for Improved Immunological Outcomes.

Britteny J Cassaidy, Brittany A Moser, Ani Solanki, Qing Chen, Jingjing Shen, Kristen Gotsis, Zoe Lockhart, Nakisha Rutledge, Matthew G Rosenberger, Yixiao Dong and 2 more

Abstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Britteny J CassaidyPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Brittany A MoserPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Ani SolankiAnimal Resource Center, University of Chicago, Chicago, Illinois 60637, United States.
Qing ChenPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Jingjing ShenPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Kristen GotsisPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Zoe LockhartPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Nakisha RutledgePritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Matthew G RosenbergerPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.ORCID https://orcid.org/0000-0002-0595-5338
Yixiao DongPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Delaney DavisPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.
Aaron P Esser-KahnPritzker School of Molecular Engineering, University of Chicago, 5640 S. Ellis Avenue, Chicago, Illinois 60637, United States.ORCID https://orcid.org/0000-0003-1273-0951

Funding

Immunoengineering Postdoctoral Training Program - Resubmission - 1T32AI153020 · NIAID · UNIVERSITY OF CHICAGO · PI ALEGRE, MARIA-LUISA, SWARTZ, MELODY ANN · 2021 to 2025
$2.1M
NIAID NIH HHS T32 AI153020
6 · The paper itself

Abstract

With the emergence of SARS-CoV-2 and the continued emergence of new infectious diseases, there is a need to improve and expand current vaccine technology. Controlled-release subunit vaccines provide several benefits over current vaccines on the market, including the use of less antigen and fewer boost doses. Previously, our group reported molecules that alter NF-κB signaling improved the vaccine's performance and improved adjuvant-related tolerability. In this report, we test how these immune potentiators will influence responses when included as part of a controlled-release poly(lactic-

Identifiers

PMID38496947
PMCPMC10938429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.